Discover oncology · 2025
Efficacy analysis of endostar combined with chemoradiotherapy and immune checkpoint inhibitors in locally advanced non-small cell lung cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Bo, Yang Yaocheng, Dong Lina, Zhuang Dunmin, Pan Shixiang, Lu Haijun
Аннотация
OBJECTIVE: Lung cancer, particularly non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related death globally, with treatment challenges persisting in locally advanced or inoperable cases. To evaluate the efficacy and adverse reactions of recombinant human endostatin (Endostar) combined with chemoradiotherapy and immune drugs in patients with locally advanced non-small cell lung cancer (NSCLC) who could not undergo surgery.
METHODS: A retrospective analysis was conducted on 190 patients with locally advanced NSCLC who could not undergo surgery. Patients were divided into group A (synchronous chemoradiotherapy combined with Endostar followed by immune consolidation therapy) and group B (synchronous chemoradiotherapy combined with Endostar followed by Endostar maintenance therapy). Treatment included continuous infusion of Endostar during radiotherapy, with a 21-day cycle. Radiotherapy was performed using intensity-modulated radiotherapy with conventional fractionation, delivering a dose of 60-66 Gy/30-33 fractions to the primary tumor and mediastinal lymph nodes over 6-7 weeks. Chemotherapy was platinum-based doublet chemotherapy. The recent efficacy, clinical benefit rate, disease progression time, overall survival time, and adverse reactions were observed.
RESULTS: The effective rates were 12% and 19.2%, and the disease control rates were 88% and 61.5% in groups A and B, respectively. The median progression-free survival (mPFS) was 29.83 months in group A and 8.73 months in group B, while the median overall survival (mOS) was 50.47 months in group A and 25.67 months in group B. The main adverse reactions in both groups were mostly grades 0-2.
CONCLUSION: Endostar combined with synchronous chemoradiotherapy followed by Endostar maintenance therapy can improve the survival of patients with locally advanced NSCLC who could not undergo surgery, without increasing adverse reactions, and has certain clinical guiding significance.
METHODS: A retrospective analysis was conducted on 190 patients with locally advanced NSCLC who could not undergo surgery. Patients were divided into group A (synchronous chemoradiotherapy combined with Endostar followed by immune consolidation therapy) and group B (synchronous chemoradiotherapy combined with Endostar followed by Endostar maintenance therapy). Treatment included continuous infusion of Endostar during radiotherapy, with a 21-day cycle. Radiotherapy was performed using intensity-modulated radiotherapy with conventional fractionation, delivering a dose of 60-66 Gy/30-33 fractions to the primary tumor and mediastinal lymph nodes over 6-7 weeks. Chemotherapy was platinum-based doublet chemotherapy. The recent efficacy, clinical benefit rate, disease progression time, overall survival time, and adverse reactions were observed.
RESULTS: The effective rates were 12% and 19.2%, and the disease control rates were 88% and 61.5% in groups A and B, respectively. The median progression-free survival (mPFS) was 29.83 months in group A and 8.73 months in group B, while the median overall survival (mOS) was 50.47 months in group A and 25.67 months in group B. The main adverse reactions in both groups were mostly grades 0-2.
CONCLUSION: Endostar combined with synchronous chemoradiotherapy followed by Endostar maintenance therapy can improve the survival of patients with locally advanced NSCLC who could not undergo surgery, without increasing adverse reactions, and has certain clinical guiding significance.